Cargando…
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted immune reaction is induced. Chimeric antigen receptor-T cell therapy is approved for patients suffering from advanced an...
Autores principales: | Totzeck, Matthias, Michel, Lars, Lin, Yi, Herrmann, Joerg, Rassaf, Tienush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123242/ https://www.ncbi.nlm.nih.gov/pubmed/35257157 http://dx.doi.org/10.1093/eurheartj/ehac106 |
Ejemplares similares
-
Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019) -
Cardiac dysfunction from cancer and cancer therapy: new pathways for the prevention of late cardiotoxicity
por: Michel, Lars, et al.
Publicado: (2021) -
Toxicity of Chimeric Antigen Receptor T Cells and its Management
por: Wudhikarn, Kitsada, et al.
Publicado: (2021) -
Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016) -
Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer—a meta‐analysis
por: Michel, Lars, et al.
Publicado: (2020)